A Phase 4 clinical trial involving liraglutide was updated on August 12, 2026. The trial, titled "Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes (ZQL007)," is currently listed with a status of recruiting.
The study is registered under identifier NCT03883412 and is designated as a Phase 4 trial. It is designed to examine exercise and liraglutide in people with type 2 diabetes. No outcome data or results have been reported as part of this update.
Liraglutide is an approved compound, and this trial reflects ongoing research activity involving its use in a Phase 4 setting. The recruiting status indicates that the trial is currently enrolling participants as of the date listed.
Readers can find more information about this trial, including full eligibility criteria and study design, through the official clinical trial registry listing. For additional context on liraglutide, readers can refer to the compound overview.